Be part of history in the making. AstraZeneca is building its first biologics manufacturing campus in Singapore – a groundbreaking USD 1.5billion investment that will serve as a global hub for innovation and excellence.

The state‑of‑the‑art facility will deliver end‑to‑end Antibody‑DrugConjugate (ADC) capabilities and small‑molecule API production, including large‑molecule monoclonal antibody manufacturing, conjugation, fill‑and‑finish operations (sterile filling, lyophilization) and final secondary packaging.

The campus will be equipped with modern digital and automation infrastructure, enabling autonomous manufacturing powered by artificial intelligence and designed for carbon neutrality, embedding sustainability into all operations.

• Drive the development and implementation of operational goals to achieve strategic objectives in asset life‑cycle management for all campus equipment and engineering infrastructure....